Skip to main content
  • Saved

Commented on 's Post

Prognostic Factors for Overall Survival in Patients With Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3 - PubMed

Prognostic Factors for Overall Survival in Patients With Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3 - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/34037282/

Prognostic factors for OS included endocrine sensitivity, nonvisceral disease, ECOG PS of 0, and no prior chemotherapy for ABC. Exploratory analyses suggest improved OS with palbociclib-fulvestrant versus placebo-fulvestrant in patients with no prior chemotherapy for ABC, prior endocrine sensitivity ...

  • 2 weeks 5 days

    Key Points
    • In this analysis of the PALOMA-3 trial, researchers identified factors that affect survival outcomes in 521 patients with advanced breast cancer (ABC) who were treated with pablociclib-fulvestrant. They also assessed the optimal timing of cyclin-dependent kinase 4/6 inhibitor therapy in these patients.
    • Endocrine sensitivity, nonvisceral disease, no prior chemotherapy for ABC, and Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 were prognostic factors for OS.
    • “These findings in combination with the current body of literature regarding OS benefit with CD 4/6 inhibitors suggest that patients receive greater clinical benefit from pablociclib plus fulvestrant if the combination is received prior to chemotherapy of HR+/HER- ABC,” concluded the authors.
    • Limitations of the current study include its post hoc, exploratory nature, as well as the small sample sizes of some subgroups.
    • Of note, the researchers stressed that all patients who received pablociclib plus fulvestrant compared with fulvestrant plus placebo attained clinical benefit despite sub-group—including those with prior chemotherapy, endocrine resistance, or multiple lines of systemic therapy. The authors recommended that these patients receive CD 4/6 inhibitor therapy for HR+/HER- ABC.